Cargando…

Factors associated with successful phase III trials for solid tumors: A systematic review

BACKGROUND: It is known that the success rates of phase III trials for solid cancers are low. The aim of this study was to investigate factors related to trial design and operation that were associated with the probability of the success of phase III trials for solid cancers based on the latest comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otsuka, Yasushi, Kaneko, Masayuki, Narukawa, Mamoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606338/ https://www.ncbi.nlm.nih.gov/pubmed/34841122 http://dx.doi.org/10.1016/j.conctc.2021.100855

Ejemplares similares

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
por: Aboshi, Masayuki, et al.
Publicado: (2014)

Approval success rates of drug candidates based on target, action, modality, application, and their combinations
por: Yamaguchi, Shingo, et al.
Publicado: (2021)

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
por: Inoue, Takashi, et al.
Publicado: (2022)

Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
por: Ogata, Akiko, et al.
Publicado: (2019)

Randomized controlled trial data for successful new drug application for rare diseases in the United States
por: Kubota, Yosuke, et al.
Publicado: (2023)

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
por: Maeda, Kojiro, et al.
Publicado: (2017)

Impact of the Economic Status of the Patient’s Country of Residence on the Outcome of Oncology Clinical Trials
por: Nishiyama, Saki, et al.
Publicado: (2022)

Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial
por: Oda, Yoshihiro, et al.
Publicado: (2022)

Phase III Soft Tissue Sarcoma Trials: Success or Failure?
por: Lee, Alexander T. J., et al.
Publicado: (2017)

Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020
por: Paratore, C., et al.
Publicado: (2022)

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020)

Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan
por: Watanabe, Tatsuya, et al.
Publicado: (2016)

A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States
por: Hoshino, Yuko, et al.
Publicado: (2022)

Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies
por: Sivendran, Shanthi, et al.
Publicado: (2015)

Solid Phase Extraction for Monitoring of Occupational Exposure to Cr (III)
por: Shahtaheri, S.J., et al.
Publicado: (2007)

Roadblocks to success for RNA CARs in solid tumors
por: Singh, Nathan, et al.
Publicado: (2015)

Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials
por: Zhang, Jing, et al.
Publicado: (2016)

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

Reporting of PPI and the MCID in phase III/IV randomised controlled trials—a systematic review
por: Brennan, Joseph, et al.
Publicado: (2023)

Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review
por: Ali, Mohammad O., et al.
Publicado: (2023)

Impact factor and citation metrics in phase III cancer trials
por: Abi Jaoude, Joseph, et al.
Publicado: (2021)

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials
por: Tanabe, Yuko, et al.
Publicado: (2016)

DNA Display III. Solid-Phase Organic Synthesis on Unprotected DNA
por: Halpin, David R, et al.
Publicado: (2004)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Systematic study of tissue factor expression in solid tumors
por: de Bono, Johann S., et al.
Publicado: (2022)

Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
por: Zhang, Jianrong, et al.
Publicado: (2018)

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
por: Balasubramanian, Adithya, et al.
Publicado: (2020)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry
por: Sakurai, Hitoshi, et al.
Publicado: (2022)

Immunotherapy in Pediatric Solid Tumors—A Systematic Review
por: Marayati, Raoud, et al.
Publicado: (2019)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens
por: Phillips, Patrick P. J., et al.
Publicado: (2017)

The Evolving Landscape of Leptomeningeal Cancer from Solid Tumors: A Systematic Review of Clinical Trials
por: Marenco-Hillembrand, Lina, et al.
Publicado: (2023)

Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials
por: Ricci, Claudio, et al.
Publicado: (2021)

Analysis of early phase and subsequent phase III stroke studies of neuroprotectants: outcomes and predictors for success
por: Minnerup, Jens, et al.
Publicado: (2014)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k7u6s0sdh8fjdiif9d48hq15k4